Francesco Fabbri

Summary

Affiliation: Morgagni-Pierantoni Hospital
Country: Italy

Publications

  1. pmc Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line
    Francesco Fabbri
    Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    J Transl Med 6:43. 2008
  2. pmc Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: a cytometric study
    Francesco Fabbri
    Department of Medical Oncology, Morgagni Pierantoni Hospital, Via Forlanini 34, 47100 Forli, Italy
    BMC Cell Biol 7:6. 2006
  3. ncbi request reprint Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells
    Silvia Carloni
    Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori I R S T, 47014 Meldola, Italy
    Curr Cancer Drug Targets 10:422-31. 2010
  4. doi request reprint Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models
    Anna Tesei
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    J Cell Mol Med 15:316-26. 2011
  5. doi request reprint Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression
    Francesco Fabbri
    Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    Prostate 70:219-27. 2010
  6. doi request reprint Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines
    Paola Ulivi
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    J Cell Physiol 220:214-21. 2009
  7. pmc Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines
    Anna Tesei
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    J Transl Med 5:52. 2007
  8. doi request reprint Activity of different anthracycline formulations in hormone-refractory prostate cancer cell lines: role of Golgi apparatus
    Francesco Fabbri
    Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    J Cell Physiol 226:3035-42. 2011
  9. pmc Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines
    Wainer Zoli
    Division of Oncology and Diagnostics, Morgagni Pierantoni Hospital, Forli, Italy
    Breast Cancer Res 7:R681-9. 2005
  10. ncbi request reprint Short interfering RNA directed against the SLUG gene increases cell death induction in human melanoma cell lines exposed to cisplatin and fotemustine
    Ivan Vannini
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    Cell Oncol 29:279-87. 2007

Collaborators

Detail Information

Publications17

  1. pmc Zoledronic acid increases docetaxel cytotoxicity through pMEK and Mcl-1 inhibition in a hormone-sensitive prostate carcinoma cell line
    Francesco Fabbri
    Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    J Transl Med 6:43. 2008
    ..In prostate cancer, the identification of drug combinations that could reduce the tumor cell population and rapidly eradicate hormone-resistant cells potentially present would be a remarkable breakthrough in the treatment of this disease...
  2. pmc Sequential events of apoptosis involving docetaxel, a microtubule-interfering agent: a cytometric study
    Francesco Fabbri
    Department of Medical Oncology, Morgagni Pierantoni Hospital, Via Forlanini 34, 47100 Forli, Italy
    BMC Cell Biol 7:6. 2006
    ..In order to increase such knowledge, we studied a number of independent biochemical and cytological modifications using cytometric methods in a bladder cancer cell line treated with the second generation taxane, docetaxel...
  3. ncbi request reprint Tyrosine kinase inhibitors gefitinib, lapatinib and sorafenib induce rapid functional alterations in breast cancer cells
    Silvia Carloni
    Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori I R S T, 47014 Meldola, Italy
    Curr Cancer Drug Targets 10:422-31. 2010
    ..These data suggest that the investigated drugs possess mechanisms of action that are independent of drug target expression, opening up further possibilities for the development of new therapeutic strategies...
  4. doi request reprint Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models
    Anna Tesei
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    J Cell Mol Med 15:316-26. 2011
    ..Our findings suggest the potential clinical usefulness of treatment with sorafenib and docetaxel for advanced gastric cancer...
  5. doi request reprint Docetaxel-ST1481 sequence exerts a potent cytotoxic activity on hormone-resistant prostate cancer cells by reducing drug resistance-related gene expression
    Francesco Fabbri
    Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    Prostate 70:219-27. 2010
    ..The aims of the present work were to examine the in vitro activity and mechanisms of action of different antitumor drug combinations in hormone-resistant prostate cancer (HRPC) cell lines...
  6. doi request reprint Role of RAF/MEK/ERK pathway, p-STAT-3 and Mcl-1 in sorafenib activity in human pancreatic cancer cell lines
    Paola Ulivi
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    J Cell Physiol 220:214-21. 2009
    ..Our results show that sorafenib exerts anti-proliferative and pro-apoptotic activity in pancreatic cancer cells. Used singly or in combination with other drugs, it could therefore represent valid treatment for pancreatic cancer...
  7. pmc Study of molecular mechanisms of pro-apoptotic activity of NCX 4040, a novel nitric oxide-releasing aspirin, in colon cancer cell lines
    Anna Tesei
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    J Transl Med 5:52. 2007
    ..In the present study, we investigated the mechanisms underlying the cytotoxicity of NCX 4040, a novel NO-aspirin with promising antineoplastic action, in in vitro human colon cancer models...
  8. doi request reprint Activity of different anthracycline formulations in hormone-refractory prostate cancer cell lines: role of Golgi apparatus
    Francesco Fabbri
    Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    J Cell Physiol 226:3035-42. 2011
    ..Of note, the activity of NLPDX in taxane-resistant DU145-R cells warrants further evaluation as second-line treatment of advanced HRPC after taxane failure...
  9. pmc Addition of 5-fluorouracil to doxorubicin-paclitaxel sequence increases caspase-dependent apoptosis in breast cancer cell lines
    Wainer Zoli
    Division of Oncology and Diagnostics, Morgagni Pierantoni Hospital, Forli, Italy
    Breast Cancer Res 7:R681-9. 2005
    ....
  10. ncbi request reprint Short interfering RNA directed against the SLUG gene increases cell death induction in human melanoma cell lines exposed to cisplatin and fotemustine
    Ivan Vannini
    Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy
    Cell Oncol 29:279-87. 2007
    ..In this context, the SLUG gene has recently been characterized as a major regulator of melanocytes and melanoma cell survival...
  11. doi request reprint Organosulfur derivatives of the HDAC inhibitor valproic acid sensitize human lung cancer cell lines to apoptosis and to cisplatin cytotoxicity
    Anna Tesei
    Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori I R S T, Meldola, Italy
    J Cell Physiol 227:3389-96. 2012
    ..Further studies are needed to confirm these preliminary findings...
  12. ncbi request reprint Schedule-dependent cytotoxic interaction between epidoxorubicin and gemcitabine in human bladder cancer cells in vitro
    Wainer Zoli
    Department of Medical Oncology, Pierantoni Hospital, Forli, Italy
    Clin Cancer Res 10:1500-7. 2004
    ..The aim of the study was to evaluate the activity of epidoxorubicin (EPI) and gemcitabine (GEM) and to define the most effective schedule in human bladder cancer cells...
  13. ncbi request reprint Molecular characterization of cytotoxic and resistance mechanisms induced by NCX 4040, a novel NO-NSAID, in pancreatic cancer cell lines
    Marco Rosetti
    Istituto Oncologico Romagnolo, Meldola, Italy
    Apoptosis 11:1321-30. 2006
    ..Moreover, the use of a specific COX-2 inhibitor (NS 398) in the experimental models showed that COX-2 hyperexpression could partially explain the resistance mechanisms to NCX 4040...
  14. doi request reprint Detection and recovery of circulating colon cancer cells using a dielectrophoresis-based device: KRAS mutation status in pure CTCs
    Francesco Fabbri
    Biosciences Laboratory, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Meldola, Italy
    Cancer Lett 335:225-31. 2013
    ..Our results present dielectrophoresis-based procedures as a new standard in single cell analysis and recovery and invite careful reflection on the value of CTCs characterization...
  15. ncbi request reprint p16INK4A and CDH13 hypermethylation in tumor and serum of non-small cell lung cancer patients
    Paola Ulivi
    Istituto Oncologico Romagnolo, Morgagni Pierantoni Hospital, Forlì Meldola, Italy
    J Cell Physiol 206:611-5. 2006
    ....
  16. pmc Inhibition of breast cancer cell proliferation in repeated and non-repeated treatment with zoledronic acid
    Toni Ibrahim
    Osteoncology Center, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, Via P, Maroncelli 40, 47014, Meldola, FC, Italy
    Cancer Cell Int 12:48. 2012
    ..abstract:..
  17. ncbi request reprint Perspectives on mTOR inhibitors for castration-refractory prostate cancer
    Salvatore L Burgio
    IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori I R S T, Via Piero Maroncelli 40, 47014 Meldola FC, Italy
    Curr Cancer Drug Targets 12:940-9. 2012
    ..Particular emphasis is also placed on the development of novel perspectives to improve the poor prognosis of patients with CRPC...